Chimeric Therapeutics Limited

Dr Rebecca McQualter

Chief Operations Officer

New investors

Team

T Cell Derived Autologous Therapies

About Cell Therapy

Pipeline

NK Cell Derived Allogeneic Therapies

Science

Governance

Announcements

Updates

Investor Hub

Home

About Us

DM Sans

Click here to visit our dedicated Entitlement Offer (NREO) page for all the information you need to participate. 

Chimeric is focussed on novel cell therapies for cancer. We have three novel cell therapies with four Phase 1 trials running at the moment.

, for gastric and pancreatic cancers and colorectal cancers , we now have a site open and recruiting in Nashville, Tennessee.


, we have a site open also in Nashville, Tennessee, for the brain cancer, Glioblastoma.

 platform, with which we're addressing blood cancer AML, and also testing in those with colorectal cancer, at MD Anderson Cancer Centre in Texas, and Case Western Reserve University.


Please reach out and ask your questions on our investor hub. I'm here to answer anything you need to know about Chimeric. I'm looking forward to engaging with you and taking Chimeric to the next level.